FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB AP	OMB APPROVAL										
OMB Number:	3235-0287										
Estimated average	o burdon										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Landry Robert E				RE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify						
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 01/23/2024								X Office (give title Other (specify below) EVP Finance CFO					
(Street)	YTOWN NY 10591				_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	(State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - No	n-Deriv	vative									Ily Owne					
		2. Transaction Date (Month/Day/Year)		ır) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A)			Benefic Owned	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 01/23/				3/2024				М		1,100) A	\$378.	98 24	,084		D			
Common Stock			01/23	3/2024				F		776	76 D \$.5 23	23,308		D			
Common Stock			01/24	24/2024				M		500	500 A		98 23	3 23,808		D			
Common Stock 01/2				/2024				F		352	D	\$951.	26 23	23,456		D			
Common Stock													2	270		I	By 401(k) Plan		
		Т	able II -											y Owned			'		
1. Title of Derivative Security (Instr. 3)	of 2. 3. Transaction 3A. Deemed Execution Date (Month/Day/Year) if any		ned n Date,	4. Transaction		5. Number of		6. Date Exercis. Expiration Date (Month/Day/Yea		sable and	7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		Beneficial Ownership t (Instr. 4)		
					Code	v	(A)		Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Non- Qualified Stock Option (right to buy)	\$378.98	01/23/2024			М			1,100	(1)		12/12/2027	Common Stock	1,100	\$0.0	13,087	7	D		
Non- Qualified Stock Option (right to buy)	\$378.98	01/24/2024			М			500	(1)		12/12/2027	Common Stock	500	\$0.0	12,587	7	D		

Explanation of Responses:

1. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Robert E. Landry 01/25/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).